tiprankstipranks
Trending News
More News >
MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Hong Kong Market

MicroPort CardioFlow Medtech Corp. (2160) AI Stock Analysis

Compare
0 Followers

Top Page

HK

MicroPort CardioFlow Medtech Corp.

(2160)

Rating:47Neutral
Price Target:
HK$1.00
▲(5.26%Upside)
MicroPort CardioFlow Medtech Corp. has a strong equity base and promising revenue growth, which are positive indicators. However, significant profitability and cash flow challenges, along with a negative P/E ratio, weigh heavily on the overall score. The technical analysis suggests potential for short-term recovery, but long-term financial improvements are necessary for a stronger outlook.

MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)

MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model

Company DescriptionMicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
How the Company Makes MoneyMicroPort CardioFlow Medtech Corp. generates revenue through the sale of its cardiovascular medical devices, particularly those used in minimally invasive procedures such as TAVI systems. The company's revenue streams include direct sales to hospitals and healthcare facilities, as well as partnerships and distribution agreements with medical device distributors and healthcare providers. The company invests in research and development to continuously innovate and expand its product offerings, which helps maintain competitive advantage and meet the growing demand for advanced cardiovascular treatments. Strategic partnerships and collaborations with healthcare institutions and research organizations also play a significant role in the company's revenue generation and market expansion efforts.

MicroPort CardioFlow Medtech Corp. Financial Statement Overview

Summary
MicroPort CardioFlow Medtech Corp. has strong revenue growth and a solid equity base, but faces significant challenges with profitability and cash flow. The negative EBIT, net income, and cash flow management issues indicate ongoing operational inefficiencies. The balance sheet strength is a positive factor but is outweighed by persistent losses.
Income Statement
45
Neutral
MicroPort CardioFlow Medtech Corp. has shown substantial revenue growth over the years, with a revenue growth rate of 7.54% from 2023 to 2024. However, the company is struggling with profitability as indicated by negative EBIT and net income, resulting in negative EBIT and net profit margins. The gross profit margin improved slightly, showing a focus on cost management, but overall profitability remains a challenge.
Balance Sheet
55
Neutral
The company's balance sheet is relatively strong with a high equity ratio of 81.74%, indicating a solid capital base. The debt-to-equity ratio is low at 0.04, reflecting minimal leverage and reduced financial risk. However, the return on equity remains negative, driven by sustained net losses, which undermines the overall financial health.
Cash Flow
40
Negative
The cash flow statement indicates significant operational challenges, with zero operating and free cash flow in the latest period. The absence of positive cash flows highlights ongoing operational inefficiencies. The company has shown improvements in reducing free cash flow deficits over the years, but cash flow management remains an area of concern.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue361.56M336.21M251.03M200.81M103.93M
Gross Profit251.21M229.93M162.13M118.70M45.38M
EBITDA-113.32M-386.05M-347.91M-126.43M-227.43M
Net Income-49.45M-471.53M-454.39M-183.26M-608.98M
Balance Sheet
Total Assets2.68B2.58B3.00B3.36B1.11B
Cash, Cash Equivalents and Short-Term Investments1.36B1.07B1.87B2.21B612.47M
Total Debt76.86M70.48M95.47M125.64M15.83M
Total Liabilities454.07M242.25M247.55M265.52M1.46B
Stockholders Equity2.19B2.33B2.75B3.10B-345.18M
Cash Flow
Free Cash Flow-270.06M-237.50M-231.60M-269.94M-167.97M
Operating Cash Flow-111.67M-206.99M-182.53M-161.50M-109.75M
Investing Cash Flow-798.50M-596.06M-179.78M-437.48M-56.42M
Financing Cash Flow-56.31M-25.61M-136.42M2.23B676.42M

MicroPort CardioFlow Medtech Corp. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.95
Price Trends
50DMA
0.89
Positive
100DMA
0.92
Positive
200DMA
0.83
Positive
Market Momentum
MACD
<0.01
Positive
RSI
55.76
Neutral
STOCH
71.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.89, and above the 200-day MA of 0.83, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 71.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2160.

MicroPort CardioFlow Medtech Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
47
Neutral
HK$2.22B-2.19%5.32%89.43%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
DE4WO
€500.81M-10.43%
75
Outperform
HK$6.78B22.7310.92%1.19%20.19%45.54%
65
Neutral
HK$7.09B35.934.39%0.82%-32.05%-54.47%
50
Neutral
HK$1.13B-27.82%-6.12%0.43%
47
Neutral
HK$286.54M0.291417.08%-20.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2160
MicroPort CardioFlow Medtech Corp.
0.95
0.12
14.46%
DE:4WO
Peijia Medical Ltd.
0.72
0.26
56.52%
HK:1789
AK Medical Holdings Ltd.
6.05
1.77
41.36%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
12.90
4.72
57.70%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.12
0.08
200.00%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.67
-2.95
-52.49%

MicroPort CardioFlow Medtech Corp. Corporate Events

MicroPort CardioFlow Announces AGM Results and Board Changes
Jun 27, 2025

MicroPort CardioFlow Medtech Corp. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were approved by shareholders. The meeting also marked the retirement of an independent non-executive director and the appointment of a new one, leading to changes in the composition of the board committees. These developments are expected to influence the company’s governance and strategic direction, potentially impacting its market position and stakeholder relationships.

MicroPort CardioFlow Announces Board Composition and Roles
Jun 27, 2025

MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure, which can influence the company’s strategic direction and governance.

MicroPort CardioFlow Announces 2025 Annual General Meeting
Jun 4, 2025

MicroPort CardioFlow Medtech Corporation has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Shanghai, China. The meeting will address several key resolutions, including the approval for the directors to repurchase shares and to issue additional shares or securities. These resolutions, if passed, could impact the company’s capital structure and shareholder value, reflecting strategic moves to enhance market positioning and operational flexibility.

MicroPort CardioFlow Acquires Full Ownership of MP CardioAdvent
May 30, 2025

MicroPort CardioFlow Medtech Corp. has announced its acquisition of the remaining 49% equity interest in MP CardioAdvent, making it a wholly-owned subsidiary. This move is part of a strategic effort to consolidate its holdings and strengthen its position in the cardiovascular device market. The acquisition is classified as a disclosable and connected transaction under Hong Kong’s Listing Rules, requiring approval from independent shareholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025